This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Camden-Clark Memorial Hospital Selects Eclipsys To Meet Clinical Excellence And Business Transformation Goals

Eclipsys Corporation (NASDAQ: ECLP), The Outcomes Company ®, today announced that Camden-Clark Memorial Hospital (Camden-Clark), a 273-bed community hospital located in Parkersburg, WV, has signed a multimillion dollar agreement to support clinical excellence and business transformation goals. New client Camden-Clark will pursue becoming a top performing hospital by replacing legacy competitor technology with the entire Sunrise Enterprise™ integrated suite of clinical and revenue cycle solutions, along with Eclipsys’ Enterprise Performance Management solution suite. Once complete, the sweeping electronic health record (EHR) and administrative software initiative will serve to improve care team efficiency, clinical decision making, while enhancing administrative processes, patient safety and throughput. The community hospital also will be positioned to achieve the expected “Meaningful Use” requirements of the American Reinvestment and Recovery Act (ARRA) of 2009. To that end, Camden-Clark will use Eclipsys’ “speed to value” implementation approach to accelerate the activation timeframe to help meet the specified timeline requirements of ARRA in order to maximize stimulus payment opportunities.

Achieving ARRA Guidelines and Improving Outcomes across the Care Continuum

“Our hospital chose Eclipsys because they share our vision to achieve top decile performance in patient quality and satisfaction and are committed to help us achieve this vision,” said Michael A. King, president and chief executive officer of Camden-Clark Memorial Hospital. “This initiative will equip our physicians with real-time access to up-to-date patient information and maximum clinical effectiveness. This investment also will improve each caregiver’s ability to make more informed decisions. The technology tools will enable a more collaborative, streamlined care environment across all our departments and disciplines. Most important, the patients and the community we serve will receive the ultimate benefit of improved healthcare for their lifetime.”

Key Solutions to Meeting Expected ARRA “Meaningful Use”

New technology solutions include Eclipsys’ leading computerized physician order entry (CPOE) system and other integrated clinical software solutions that document and automate care at the bedside, critical care units, laboratory, radiology department and the emergency room. An integrated pharmacy system will set the stage for closed loop medication administration processes and expedite more accurate handoffs between clinicians and pharmacist to reduce the chance for medication errors. To further support patient safety, Camden-Clark selected Eclipsys’ Knowledge-Based Medication Administration™ to help ensure the right patient receives the right medication via a handheld device caregivers will use to scan medication bar codes at the bedside. Web portal technology also will give Camden-Clark physicians secure, Internet access to patient information, such as test results and vital signs to enable quicker, more informed patient care decisions, regardless of whether the physician is at the hospital, home or office.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
AAPL $124.49 -1.50%
FB $82.16 -1.20%
GOOG $548.46 -0.65%
TSLA $188.77 -0.94%
YHOO $44.44 -1.10%

Markets

DOW 17,776.12 -200.19 -1.11%
S&P 500 2,067.89 -18.35 -0.88%
NASDAQ 4,900.8850 -46.5560 -0.94%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs